CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.9507
-0.0593 (-5.87%)
At close: Apr 24, 2026, 4:00 PM EDT
0.9000
-0.0507 (-5.33%)
After-hours: Apr 24, 2026, 5:54 PM EDT
CytoMed Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Revenue doubled to SGD 156,000 for H1 2025, driven by new blood banking services, but net loss widened to SGD 2.25 million. Clinical pipeline advanced, with new collaborations and financing initiatives, while cash balances declined.
Fiscal Year 2024
-
Reported H1 2024 net loss of $803,000, with strong cash reserves and a significant increase in other income. Transitioning to clinical stage in Q4 2024, supported by a national grant and a strategic cord blood bank acquisition.